Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 26-May 2015. Module: Canada Health Infoway English module (core metadata concept)
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 137381000087111 | GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | en | Fully specified name | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 95861000087119 | GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 95871000087111 | HPV-9 GARDASIL 9 MC | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 97161000087117 | VPH-9 GARDASIL 9 MC | fr | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway French module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | est un(e) (attribut) | Product manufactured as parenteral dose form (product) | true | Inferred relationship | Some | ||
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | Plays role | Active immunity stimulant role (role) | true | Inferred relationship | Some | ||
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Human papillomavirus type 11 L1 capsid protein antigen | true | Inferred relationship | Some | 7 | |
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Human papillomavirus type 16 L1 capsid protein antigen | true | Inferred relationship | Some | 8 | |
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | Count of base of active ingredient | un | false | Inferred relationship | Some | ||
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | Has supplier | Merck Canada Inc. (supplier) | true | Inferred relationship | Some | ||
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Antigen of Human papillomavirus type 33 L1 capsid protein (substance) | true | Inferred relationship | Some | 2 | |
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | Count of active ingredient | neuf | false | Inferred relationship | Some | ||
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Human papillomavirus type 58 L1 capsid protein antigen | true | Inferred relationship | Some | 5 | |
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Antigen of Human papillomavirus type 52 L1 capsid protein (substance) | true | Inferred relationship | Some | 4 | |
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | a une forme pharmaceutique (attribut) | forme pharmaceutique pour usage parentéral (forme pharmaceutique) | true | Inferred relationship | Some | ||
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Human papillomavirus type 18 L1 capsid protein antigen | true | Inferred relationship | Some | 9 | |
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Human papillomavirus type 45 L1 capsid protein antigen | true | Inferred relationship | Some | 3 | |
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Antigen of Human papillomavirus type 31 L1 capsid protein (substance) | true | Inferred relationship | Some | 1 | |
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Human papillomavirus type 6 L1 capsid protein antigen | true | Inferred relationship | Some | 6 | |
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | est un(e) (attribut) | Vaccine product containing only Human papillomavirus 9 serotypes antigens (medicinal product) | false | Inferred relationship | Some | ||
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Human papillomavirus vaccine (substance) | false | Inferred relationship | Some | 1 | |
| GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) | est un(e) (attribut) | Vaccine product containing only Human papillomavirus 6, 11, 16, 18, 31, 33, 45, 52 and 58 antigens (medicinal product) | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Administered tradename codes for vaccines reference set (foundation metadata concept)
FHIR